肺血栓栓塞症核素肺通气/灌注显像操作规程专家共识
该共识由工作组经多医院调研和专家研讨制定,涵盖V/Q显像的检查流程、诊断方法与注意事项,旨在规范操作及在PTE诊断中的应用。共识给出10条推荐,涉及显像剂选择、患者准备、给药剂量、过敏试验、采集方案及报告措辞等,并标注共识水平。
要点
- 通气显像首选99mTc-Technegas,备选99mTc-DTPA气溶胶。
- 灌注显像前建议吸氧2-4 L/min、5-10分钟以减少假阳性。
- 灌注显像推荐给予20万-70万颗粒,活度120-240 MBq。
核心结论
- 共识规范了V/Q显像操作流程及在PTE诊断中的应用,并形成10条推荐。
研究设计与样本
- 工作组经多所医院核医学科调研和专家研讨后制定本专家共识。
主要发现
- 共识涵盖检查、诊断方法和注意事项,并给出10条推荐及共识水平。
关键数值与推荐
- 推荐1:通气显像首选99mTc-Technegas,制备时建议用无水乙醇润湿坩埚,备选99mTc-DTPA气溶胶(共识水平100%)。
- 推荐2:灌注显像前建议吸氧,流量2-4 L/min、时长5-10分钟(共识水平83.3%)。
- 推荐3:灌注显像给予20万-70万颗粒(平均约40万),活度120-240 MBq(3-6 mCi);重度肺动脉高压、右向左分流或单肺移植史者减至10万-20万颗粒(共识水平83.3%)。
- 推荐4:注射前轻摇匀99mTc-MAA,患者仰卧正常潮气量呼吸,经通畅静脉通路缓慢注射,避免血液回流(共识水平100%)。
- 推荐5:有蛋白过敏史者灌注显像前做皮试,前臂注射0.1 ml 99mTc-MAA观察15-20分钟,阳性不建议灌注显像(共识水平83.3%)。
临床怎么用
- 按共识推荐选择显像剂、准备患者、控制颗粒数与活度,规范采集与报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radionuclide pulmonary ventilation/perfusion (V/Q) imaging is an important non-invasive tool for diagnosing pulmonary thromboembolism (PTE) and is used for screening, follow-up, and assessment of treatment response of PTE and chronic thromboembolic pulmonary hypertension (CTEPH). Currently, hospitals in China differ in their use of planar and tomographic acquisition methods for V/Q imaging, and interpretation requires a high level of expertise among nuclear medicine physicians. After surveying the nuclear medicine departments of multiple hospitals and holding expert discussions, the working group developed the Expert consensus on the operational protocol for radionuclide pulmonary ventilation/perfusion scintigraphy of pulmonary thromboembolism. This consensus covers examination procedures, diagnostic approaches, and precautions, with the aim of standardizing the clinical application of V/Q imaging procedures and their clinical application in PTE diagnosis. The following recommendations were formulated.Summary of RecommendationsRecommendation 1: For ventilation imaging, 99mTc-Technegas is recommended as the preferred radiopharmaceutical. During the preparation of Technegas, the working group recommends wetting the crucible with anhydrous ethanol before the addition of the sodium pertechnetate solution to improve the efficiency and quality of Technegas generation. If Technegas is unavailable, 99mTc-Diethylenetriaminepentaacetic acid (99mTc-DTPA) aerosol may be used as an alternative (Consensus level: 100%).Recommendation 2: Routine supplemental oxygen is suggested before pulmonary perfusion imaging to prevent false-positive images caused by pulmonary vasospasm. The recommended oxygen flow rate is 2-4 L/min, with an inhalation duration of 5-10 minutes (Consensus level: 83.3%).Recommendation 3: For pulmonary perfusion imaging, 200 000-700 000 radiopharmaceutical particles (mean, approximately 400 000) should be administered, with the recommended activity of 120-240 MBq (3-6 mCi). For patients with severe pulmonary hypertension, conditions with right-to-left heart shunting, or a history of single-lung transplantation, the particle number should be reduced to 100 000-200 000 (Consensus level: 83.3%).Recommendation 4: Gently agitate and homogenize the suspension of 99mTc-macroaggregated human serum albumin (99mTc-MAA) prior to injection. With the patient supine and breathing at normal tidal volume, slowly inject the tracer over several respiratory cycles through a patent intravenous line, continuously monitoring for adverse reactions; discontinue immediately if discomfort occurs. Strictly avoid backflow of blood into the syringe, which may cause particulate aggregation and bolus formation, leading to artifactual hot spots (Consensus level: 100%).Recommendation 5: For patients with protein allergies, a routine skin test is recommended before pulmonary perfusion imaging. Inject 0.1 ml of 99mTc-MAA suspension into the appropriate part of the forearm and observe for 15-20 minutes. If there is no positive reaction, perfusion imaging can be proceeded, with close observation and emergency medications on standby. If the skin test is positive, pulmonary perfusion imaging is not recommended. Routine skin testing is not indicated in patients without a history of allergy (Consensus level: 83.3%).Recommendation 6: For the 2-day acquisition protocol, perform pulmonary perfusion imaging on the first day. If the result is abnormal, perform pulmonary ventilation imaging the following day to aid diagnosis; if the perfusion imaging result is normal, pulmonary ventilation imaging may be omitted (Consensus level: 83.3%).Recommendation 7: For pregnant women with suspected PTE, if V/Q imaging is considered necessary after clinical assessment, a 2-day protocol is recommended. Dose reduction is recommended for lung perfusion imaging, the recommended dose of 99mTc-MAA is 50 MBq (1.35 mCi) (Consensus level: 100%).Recommendation 8: When the 1-day acquisition protocol is used, perfusion imaging may be performed immediately after completion of ventilation imaging. To ensure the clarity and accuracy of pulmonary perfusion imaging, the perfusion count rate should be 3-4 times the ventilation count rate (Consensus level: 100%).Recommendation 9: Avoid ambiguous phrasing such as "possible pulmonary embolism" in image reports. Interpretations should provide a definitive conclusion, such as "pulmonary embolism present", "pulmonary embolism absent", or another specific conclusion, after excluding other causes of impaired pulmonary perfusion (e.g., Takayasu arteritis, mediastinitis or pulmonary arterial sarcoma). When the diagnosis remains uncertain, the report should state, "pulmonary embolism cannot be excluded; correlation with clinical findings and other imaging examinations is recommended" to support subsequent clinical assessment and therapeutic decision-making (Consensus level: 100%).Recommendation 10: For patients with CTEPH, visual semi-quantitative analysis (Begic/Meyer score) may serve as an adjunctive tool for efficacy assessment after percutaneous pulmonary balloon angioplasty (BPA) or pulmonary endarterectomy (PEA). Where institutional resources permit, structured reporting is encouraged to improve the clarity and reproducibility of segmental impairment documentation (Consensus level: 100%). 放射性核素肺通气/灌注(V/Q)显像是无创诊断肺血栓栓塞症(PTE)的重要手段,用于 PTE 和慢性血栓栓塞性肺动脉高压(CTEPH)的筛查、随访及疗效评估。目前国内医院在V/Q 显像的平面和断层采集方式上存在差异,且该显像对核医学医生诊断水平要求较高。为此,工作组在多所医院核医学科进行调研并经专家研讨后,制订了《肺血栓栓塞症核素肺通气/灌注显像检查操作规程专家共识》,涵盖检查、诊断方法和注意事项等内容,以规范 V/Q 显像操作及其在 PTE的临床应用。.
引用
- [Expert consensus on the operational protocol for radionuclide pulmonary ventilation/perfusion scintigraphy of pulmonary thromboembolism]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42811564. doi:10.3760/cma.j.cn112147-20260602-00327
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。